CHARLESTON, S.C., Nov. 3, 2010 (GLOBE NEWSWIRE) -- Revolutions Medical Corporation (OTCBB:RMCP) announced today that due to the launch of its 3ml RevVac Safety SyringeTM during the Medica show in Dusseldorf, Germany and the enormous interest that the launch has received from healthcare professionals and corporations in Europe, the company will host an additional reception in London on Saturday, November 20th from 7:30 PM - 9:30 PM at the Landmark Hotel, Tower Suite. Anyone interested in attending the reception can RSVP on the company's website at www.revolutionsmedical.com.
With the recent passage of legislation in the European Union (EU) on new requirements to prevent accidental needlestick injuries, the EU is sending the directive to make the work environment safer for healthcare professionals. There are over 1 million accidental needlestick injuries every year in Europe. The costs associated with the lab testing, treatment, recovery and work stoppage from these needlesticks have been skyrocketing, not to mention the anxiety and hardships for the healthcare professional. Ron Wheet, the company's CEO, stated: "We believe that our RevVac Safety Syringe can virtually eliminate these accidental needlestick injuries and the spread of potentially fatal blood borne diseases such as HIV, Hepatitis B and C." For more information, go to these two links http://www.healthfirsteurope.org and http://www.paramedicpractice.com/comment.
Mr. Wheet added: "I am very pleased that we have completed the designs for both the 5ml and 10ml fixed needles before we head to Europe to introduce and launch sales for our 3ml RevVac Safety Syringe. We plan to complete our RevLokTM interchangeable needle design for the 3, 5 and 10ml sizes, along with the fixed needle 1ml design, by the end of the first quarter of 2011. We also see a significant opportunity in the rapidly growing prefilled syringe market segment and are working diligently on a prefilled syringe product line using our patented vacuum technology designs." Mr. Wheet continued: "One of our goals for 2011 is to be able to manufacture and roll out these additional products to capture these lucrative markets."
About Revolutions Medical Corporation
Revolutions Medical is a safety medical device and software application company. Its products include the RevVac Safety Syringe (FDA approved) and the RevColorTM, RevDisplayTM and Rev3DTM software solutions and proprietary tools that are compatible with standard MRIs and standard Picture Archiving Computer Systems (PACS). The software suite's functionality includes sorting of images, color, 3D and automatic segmentation of images.
CEO Ron Wheet Audio Interview:
http://ir.stockpr.com/revolutionsmedical/media-center/view/43/wallstreet-reporter-interview-with-ron-wheet-ceo
RevVac Safety Syringe Demonstration Video:
http://www.revolutionsmedical.com/videos/revac_directions_final.wmv
RevColor MRI Video:
http://www.revolutionsmedical.com/RevMed-ColorMRI-Video.php
To be added to the Revolutions Medical investor email list, please email Skey@revolutionsmedical.com with RMCP in the subject line.
Become a RevMed fan and follow the Company on Facebook -- visit http://www.Facebook.com/Revmed
FORWARD-LOOKING STATEMENTS
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could, and some cases likely will, materially affect actual results, levels of activity, performance or achievements. These risks include: the company may not be able to complete its RevLok interchangeable needle designs by the end of the first quarter of 2011 due to unexpected engineering issues the company may not obtain FDA approval to market its new syringes when it expects; and the company may not be able to penetrate the markets it is targeting on the schedule it anticipates or at all, due to possible problems with designing, manufacturing, marketing and selling the products, obtaining the necessary financing and competing with larger competitors that have greater resources and well-established marketing and sales channels. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.